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Abstract Alzheimer’s disease (AD) presents one of the
leading healthcare challenges of the 21st century, with a
projected worldwide prevalence of >107 million cases by
2025. While biomarkers have been identified, which may
correlatewithdiseaseprogressionorsubtypeforthepurposeof
disease monitoring or differential diagnosis, a biomarker for
reliable prediction of late onset disease risk has not been
available until now. This deficiency in reliable predictive
biomarkers,coupled with the devastating nature of the disease,
placesAD ata high priority forfocus by predictive, preventive
and personalized medicine. Recent data, discovered using
phylogenetic analysis, suggest that a variable length poly-T
sequencepolymorphismintheTOMM40 gene, adjacent to the
APOE gene, is predictive of risk of AD age-of-onset when
coupled with a subject’s current age. This finding offers hope
for reliable assignment of disease risk within a 5-7 year
window, and is expected to guide enrichment of clinical trials
in order to speed development of preventative medicines.
Keywords Alzheimer’s disease.Personalized medicine.
Phylogenetic analysis.Translocase of outer mitochondrial
membrane (TOMM40).Apolipoprotein E.Poly-T variant
“An ounce of prevention is worth a pound of cure”
The ultimate goal of modern healthcare is to reduce the
burden and costs associated with disease risk, monitoring
and treatment by utilizing prevention programs in a cost-
effective manner. While it is considered common sense that
“an ounce of prevention is worth a pound of cure”, there
are few examples where active intervention strategies have
been successfully and systematically developed, with the
obvious exception of vaccines. The paucity of prevention
therapies is not surprising, given the high benefit-risk ratio
required when administering active drugs to (currently)
healthy individuals. It is therefore critical to develop
diagnostics that pinpoint the indicated subpopulation for
which the benefit-risk profile is maximized and the
intervention is clearly justified. Such diagnostics need to
demonstrate clinical utility, as well as rigorous technical
performance characteristics. The decisive test of such a
diagnostic hinges on its proven predictive value character-
istics, which would then be adopted into routine use by
practicing physicians and healthcare insurers. Therefore,
this review first evaluates the characteristics of clinically
useful diagnostics in general, and then focuses on genetic
markers and diagnostics for Alzheimer’s disease (AD).
Finally, we describe a novel genetic marker for AD and
discuss its application in the design of a prevention/delay of
disease onset clinical trial that may directly impact medical
practice.
Properties of clinically useful biomarkers
Whattransformsabiomarkerintoaclinicallyusefuldiagnostic?
Evidence-based medicine guidelines outline a sequence of
steps that establish the Analytical validity, Clinical validity,
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of diagnostic and prognostic tests of a biological or genomic
nature [1, 2]. The evidence gathered throughout the ACCE
process should be conducted according to appropriately
documentedgoodoperationalpractices withrespecttosample
collection, storage and handling. The initial and most
standardized step requires demonstration of high sensitivity,
specificity and reproducibility of the test’sr e s u l t s ,i no r d e rt o
ensureits technical accuracy in capturing the targeted genetic
polymorphisms. Once the analytical performance of the test
is validated in vitro, the biomarker is tested for clinical
validity versus endo-phenotypes or quantitative clinical end-
points. At this stage, the performance of the diagnostic is
tested for sensitivity, specificity and reproducibility in
accurately measuring the clinically relevant end-points.
Clinical validity can be studied retrospectively, using previ-
ously collected samples, as long as the appropriate samples
were collected from the vast majority of cohort participants
with the appropriate informed consent.
The third component of the guidelines focuses on clinical
utility and is the ultimate test of impact of the diagnostic on
health outcomes. While during the course of clinical validity
testing the value of the diagnostic is projected based on
technical performance and market estimates, the “clinical
utility” step is designed to test these hypotheses in the context
of healthcare management. This has become a pivotal
component of clinical decision making, whether as part of a
drug development pipeline or in the context of medical
practice. Clinical utility studies are designed to optimize
testing conditions and quantify the predictive value of the
novel diagnostic in the context of controlled clinical settings.
Once validated, further studies may be conducted to assess
cost-effectiveness and adoption characteristics in real-world
clinical settings and may employ comparative effectiveness
models in order to weigh the novel, biomarker-integrated
treatmentalgorithmsagainststandard-of-care[3]. Other aspects
thatneedtobeconsideredinadditiontodemonstratingvalidity
and utility of a biomarker include Ethical, Legal and Social
Issues (ELSI) that arise when introducing the diagnostic to the
market. Eventually, the success of a diagnostic relies on the
successful implementation of each of the above ACCE model
components [2], as reflected via endorsement by regulators,
incorporation into practice guidelines, influence on physician
behaviors and adoption into reimbursement policies [4].
A direct method for demonstrating the most significant
component of the ACCE framework – the clinical utility of
a biomarker - utilizes a prospective study design in parallel
to a drug development trial. To this end, the FDA issued a
concept paper that proposes a framework for the co-
development of drugs and diagnostics via an integrated
combination regulatory path [5]. A pioneering example for
drug/diagnostic (Rx/Dx) co-development in the AD thera-
peutic area is outlined in the following sections.
The challenge of Alzheimer’s disease management
AD has become an area of considerable unmet medical
need in recent decades. Currently, over 5 million Americans,
or more than 10% of citizens 71 years of age or older, suffer
from AD and estimates are that 1 new case of AD develops
every 7 seconds, with a higher rate of increase in developing
countries [6, 7]. Unless effective therapies for preventing or
delaying AD onset are developed, it is projected that >16
million Americans and >107 million people worldwide will
suffer from AD by 2050. Delaying AD onset by as few as
one or two years is speculated to decrease the worldwide
disease burden in 2050 by 12 million or 23 million cases,
respectively [8]. In addition to the devastating losses of
quality of life and productivity experienced by AD patients,
their care-givers spend greater than $94 billion annually
(last updated in 2004) in the US on AD-related healthcare
costs [9]. These numbers are expected to increase substan-
tially with the anticipated growth in both population and
life expectancy, particularly as the “baby-boom” generation
ages. The increased burden, however, cannot be offset by
effective medical management using currently available
AD healthcare strategies. There are currently no long-
term, effective treatments for AD, and no life-style changes
have been proven to substantially delay or prevent its
onset [10].
Why does AD present such a formidable challenge to
healthcare management and novel drug discovery? AD is a
neurological disorder that presents as decline in domains of
cognition, memory and activities of daily living. The
typical pattern of memory loss involves impaired recall of
learned or previously known information, reflecting medial
temporal lobe (and possibly basal forebrain) dysfunction.
While overlapping, this pattern is distinct from normal aging,
where learning efficiency, working memory and psychomotor
speed (activities related to frontal lobe function) are reduced
[11]. The two histopathological hallmarks of AD brains are:
(1) intracellular neurofibrillary tangles (NFT) resultant from
the aggregation of hyperphosphorylated tau proteins; and (2)
extracellular senile plaques, composed primarily of amyloid
beta (Aβ) protein. Unfortunately, clinical characterization of
the disease, through impaired behavioral autonomy or
learning and cognition deficits, is complex, subjective and
includes a range of possible differential diagnoses, deeming
definitive AD diagnosis contingent on autopsy. The gradual
progression of the disease has allowed researchers to identify
an intermediate phenotype entitled mild cognitive impairment
(MCI) that may allow for early diagnosis and development of
predictive and preventive models targeted at arresting or
delaying the progression to AD stages. By focusing research
efforts on the phenotypic definition of MCI, researchers may
eventually be able to prevent or delay conversion into AD in
this at-risk population. However, it is important to note that
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10-15%. Moreover, individuals with MCI tend to develop
AD, but they may also develop other forms of non-AD types
of dementia, such as frontotemporal dementia (FTD). MCI
patients can also maintain a steady level of impairment
without any progression in severity [12]. Overall, the late
onset of AD and its intermediate phenotype, the heteroge-
neous presentation patterns and the sporadic manifestation
make research, diagnosis and prognosis challenging.
Genetic markers of Alzheimer Disease
Genetic diagnostics measure DNA polymorphisms that are
associated with biological or clinical traits. Genetic markers
originating from germ line polymorphisms (as opposed to
somatic mutations) can be detected in samples of blood,
saliva or differentiated non-cancerous tissues at any time-
point because they are static in nature. Such measurements
can serve as predictive diagnostics early on in life, and when
combined with other dynamic markers (such as serum protein
levels or even age) may provide reliable and accurate
composite scores for probability of disease risk, progression
or treatment response within a short window of time. Such
composite predictors are expected to contribute substantially
to the development of medical management guidelines [13].
AD has a strong genetic component, with up to 80%
heritability as estimated from twin-concordance studies
[14]. The disease is roughly categorized into two main
subtypes: 1) autosomal dominant, early onset AD, defined
by disease presentation before the age of 61, is accounted
for by familial AD (FAD) and 2) “sporadic” (non-familial)
AD, most commonly termed late onset AD (LOAD), where
symptomatic presentation generally starts after the age of 55.
For research purposes LOAD is usually defined as >60 years
of age to avoid overlap with the familial early-onset forms.
Most of the successes registered for AD genetic research
have been reported for the Mendelian forms of the disease,
the autosomal dominant FAD. Rare mutations have been
identified in three different (yet biologically associated)
genes: amyloid precursor protein (APP)[ 15], presenilin-1
(PSEN1)[ 16], and presenilin-2 (PSEN2)[ 17, 18]. However,
FAD is rare and accounts for approximately 10% of early-
onset AD and less than 1% of all AD cases [19]. The most
common form of AD is LOAD [20], and the only firmly
established genetic risk factor for LOAD is the E4 allele of
the APOE gene [21], as detailed below. Collectively, genetic
variations in APP, PSEN1, PSEN2 and APOE are estimated
to account for only 25-50% of the overall genetic risk for AD
[22, 23]. It is therefore clear that other susceptibility genes
remain undiscovered, including the possibility of finding a
single genetic variation with a higher positive predictive
value.
APOE and Alzheimer’s disease
The apolipoprotein E (APOE) gene encodes a major
apolipoprotein that is synthesized chiefly in the liver, but
also in a range of other organs, including the brain [24]. The
protein product, apoE, acts primarily as a transporter of
cholesterol and lipids among various cells of the body, but it
has also been proposed to serve other important functions in
both physiology and pathology [24]. The discovery of
APOE’s involvement in LOAD and the identification of the
E4 at-risk allele were first reported in 1993 [21, 25]. It is
important to note, that the discovery of the association
between sequence variations in the APOE gene and clinically
meaningful variability in AD risk pinpointed the pivotal role
that apoE plays in the pathogenesis of AD, which had not
been fully explored beforehand. In fact, apart from age,
APOE4 status is the most validated AD risk factor. Con-
versely, the rare E2 allele has been associated with protection
against LOAD compared with both the E4 allele and the
more common E3 allele [21]. Overall, it has been reported
that heterozygotes for the E4 allele are three to four times as
likely to develop AD than non-carriers [26], and the number
of copies (one or two alleles) of E4 carried is proportional to
level of risk [27, 28]. As seen in the initial reported finding
depicted in Fig. 1 [28], the Kaplan-Meier survival graph
shows a characteristic curve for each one of the genotype
carrier groups: the number of E4 copies carried is signifi-
cantly associated with disease manifestation age, with E4/E4
carriers showing the earliest disease onset. This association
of APOE4 with the lower age of disease onset, in addition to
its association with overall disease risk, has also been
repeatedly confirmed by independent groups [21, 29–35].
Functional research heralded by the 1993 discovery has
identified multiple pathways in which apoE is involved in
LOAD pathoetiology [36]. Indeed, abnormality in these
processes has been shown to associate with the sequence,
structure and biochemical distinctions between E4 and E3
or E2 alleles. In fact, apoE4 is the only molecule that has
to-date been associated with the entire spectrum of biochem-
ical disturbances characteristic of AD: Aβ deposition, tangle
formation, oxidative stress, lipid homeostasis deregulation,
synaptic plasticity loss and cholinergic dysfunction [36, 37].
Given the fact that the APOE4 allele frequency is quite high
(∼0.15 in Caucasians [38]), asymptomatic carriers have long
been studied as a convenient and informative AD research
model. In this way, AD-like structural and physiological
changes have been discovered and shown to exist years
before the symptomatic onset of memory loss and dementia
[39]. This has been a key component in the discovery and
development of disease biomarkers, including neuroimaging.
However,theusefulnessof thesebiomarkersandAPOE testing
in clinical practice does not meet clinical utility criteria due to
insufficient sensitivity, specificity and cost-effectiveness [40].
EPMA Journal (2010) 1:293–303 295Due to this fact and to the lack of preventative or curative
measures many believe that prediction in healthy individuals
is unethical and the consensus recommendation discourages
genetic testing outside research settings.
Genome-wide association studies of Alzheimer’s disease
Genome-wide association studies (GWAS) use screening
technology to test a pre-defined set of common single
nucleotide polymorphisms (SNPs) and large copy number
variations (CNVs) across the entire genome against various
phenotypic traits in a statistical association model. Overall,
GWAS conducted in large cohorts have proven successful
in suggesting a number of genetic variants of moderate and
smalleffectsizesforcomplexdiseases,includingneurological
disorders such as schizophrenia, autism spectrum disorders
and AD [41, 42]. These reports have been most useful in
confirming discoveries made in the last few decades based
on linkage and candidate gene studies and have suggested
novel regions of interest for further in-depth research, as has
been successfully demonstrated in the field of diabetes
susceptibility research, particularly with respect to TCF7L2
[43, 44]. However, several limitations hinder the translation
of GWAS findings from bench to bedside: (1) these
technologies screen binary SNPs that serve also as proxies
for some large CNVs, but are less suitable for the study of
other smaller structural variation (e.g. polymononucleotide
tracts, trinucleotide repeats, small insertion/deletions, etc);
(2) markers selected for inclusion in these off-the-shelf high-
throughput chips are based on co-occurrence probability (i.e.
Linkage Disequilibrium, LD) and common allele frequency
(5% or higher for the most part). As a result, polymorphisms
with low frequency and high LD to a common SNP are
excluded. However, it is becoming evident that often these
lesscommon polymorphisms are the major, ifnot sole, source
of association signal [45] (see further discussion below); (3)
coverage of regions is generally even across the genome, but
specific candidate genes of interest are often insufficiently
represented; (4) rare, yet functionally validated markers in
candidate genes of interest are often not included; (5)
statistical approaches focus mainly on single markers,
yielding results that are less robust due to multiple testing.
Moreover, the effect sizes generally reported for common
disease GWAS are marginal and their projected clinical
utility has been particularly disappointing [46]. In summary,
GWAS serve to highlight blocks of genetic regions of
interest for association research. However, the pinpointing of
causal variants, gene-gene and gene-environment interaction
effects warrants increased resolution of the genetic variation
within a candidate gene region, as well as more powerful
and biologically plausible approaches to their analysis [47].
Since the association of APOE with AD was discovered,
nearly 1,000 papers have been published reporting and
refuting associations of AD with hundreds of genetic
variants in different genes [42]. Recently, a meta-analysis
study suggested that no more than a dozen reproducible
associations between genomic regions and AD risk have
actually been found [42]. Furthermore, about a dozen
GWAS of sporadic LOAD have been published to date.
The papers confirm that markers in the vicinity of APOE
represent the major susceptibility genomic region for the
disease. As illustrated in Table 1, no other AD association
in the human genome remotely approaches the same level
of statistical significance or effect size as the genomic
region containing APOE [29, 30, 33, 48–56]. It should be
emphasized that the two SNP determinants for APOE
genotype are not included on the commercial platforms
commonly used for GWAS, and the major SNPs that have
extraordinarily statistical significance in the AD GWAS
publications are located in the TOMM40 gene region and
not in APOE. In other words, although findings are usually
referred to in the literature as associated with the AOPE LD
region, the measurements commonly defining this region
are rather TOMM40 polymorphisms.
TOMM40 variable length polymorphism: increasing
diagnostic prediction power and enabling a disease
prevention trial
The hypothesis that abnormal energy metabolism is a funda-
mental feature of AD pathology was proposed in the 90’s[ 28,
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Fig. 1 Alzheimer’s disease age of onset curves by APOE genotype, based
on the information available in 1994 (adopted from [28]). Age of onset for
LOAD, sporadic AD and control subjects as published in 1994 [28]. The
age-of-onset is scored as a function of the individual’s APOE genotype.
Onset curves were estimated by Kaplan-Meier product limit distributions
296 EPMA Journal (2010) 1:293–30357–59]. Indeed, cerebral metabolic rate abnormalities precede
any evidence for functional impairment by neuropsychological
testing or for brain atrophy as seen in neuroimaging byseveral
decades [60]. Evidence is amassing to support the hypothesis
that defective mitochondrial metabolism and function is the
instigating event of pathological changes that result in AD
[61]. For instance, mitochondrial dysfunction in AD brains
correlates with accumulation of Aβ [62–64]a n dA P P[ 65],
as well as presence of apoE4 fragments, in mitochondria,
causing loss of dynamic functions resulting in decreased
synaptodendritic regeneration and subsequent neuronal cell
death [65, 66]. Deposition of these proteins is also associated
with decreased glucose and oxygen utilization [67, 68].
Furthermore, it has been shown that in the mitochondrion
APP forms stable complexes with the translocase of the outer
mitochondrial membrane 40 (TOM40) import channel
[69], and that the transport of Aβ into the mitochondrion is
mediated by the same TOM40 pore, further promoting
neurotoxicity.
The significant genetic finding discussed in detail by
Roses et al. [70] and outlined below is that a variable-length,
deoxythymidine homopolymer (poly-T) in the gene encoding
TOM40 (TOMM40) is associated with age-of-onset of AD,
the major endo-phenotype of the disease. It is critical to
note that the TOMM40 gene is adjacent to, and in high LD
with, APOE, and the evolutionary relationship between the
two genes inherited together on the same strand dictates
that some specific TOMM40 variants are uniquely associated
with each of the APOE alleles.A P O E 4alleles are linked to
long poly-T variants of the rs10524523 locus approximately
98% of the time, while phylogenetic analyses clearly demon-
strate a separate genetic origin of APOE3 strands, linked to
either very long or short poly-T variants. Thus, a poly-T
variant in the TOMM40 gene sub-divides APOE3 variants into
high risk (very long) alleles and low risk (short) alleles,
challenging the commonly acceptedhypothesisthatAPOE3 is
AD risk-neutral. This finding explains the current heteroge-
neity in AD age-of-onset registered within APOE3 carriers
(Fig. 1), and offers the potential to predict the 5-7 year risk
of disease onset in individuals carrying the APOE3/3,
APOE3/4 and APOE4/4 genotypes, making up ∼85% of all
AD cases. Additionally, the functional relevance of genetic
polymorphisms in the TOMM40 gene region has been
discussed recently: First, a combined set of three SNPs
within the TOMM40 gene, one APOE promoter SNP and
two SNPs within distal APOE enhancer elements was
recently reported to predict CSFAPOE levels [71]. Second,
overlapping or linked SNPs spanning the entire APOE and
TOMM40 region were reported to be associated with
sporadic AD case-control analyses in all published GWAS
with extraordinarily significant p-values, as clearly demon-
strated in Table 1 [29, 49–54]. The three SNPs with the
highest significance were all from TOMM40.
TheTOMM40 finding was enabled by a research approach
that combined both intensive high resolution Sanger sequenc-
ing and the employment of phylogenetic statistical methodol-
ogy. This combined strategy is likely to be successful in the
study of other traits forwhich heritability has been shown to be
high but the complex genetic architecture leading to, or
modifying, the disease phenotypes hinders the effectiveness
of conventional statistical and technological approaches.
Similar approaches to the one employed herein are routinely
used to study the evolution of simpler genomes, such as those
of viruses and bacteria, and are particularly useful in annual
vaccine production against flu viruses. However, it had not
been commonly used as a method for complex disease
susceptibility investigations, due to the size and complexity
of the human genome. Currently the method is only
practical if there are other indications that a particular
genomic locus or region is involved in the phenotype of
interest. In order to maximize the power of the method and
our ability to discover the “missing heritability” residual to the
APOE4 carriage effect, the entire region spanning the APOE-
TOMM40 genes was interrogated by deep Sanger sequenc-
ing. In other words, sequencing was performed in long
DNA stretches that permitted incontrovertible assembly of
co-occurrence combinations (also termed haplotypes) with
specific APOE alleles. Deep sequencing also reliably detected
small repeat elements such as poly-T variants. The resultant
polymorphic map of common and rare, binary and multi-
variate polymorphisms was then analyzed using phylogenetic
methods.
About a dozen GWAS of sporadic LOAD have been published to date. The papers
confirm that markers in the vicinity of APOE represent the major susceptibility genomic
region for the disease. As illustrated in Table 1, no other AD association in the human
genome remotely approaches the same level of statistical significance or effect size as the
genomic region containing APOE. It should be emphasized that the two SNP determinants
for APOE genotype are not included on the commercial platforms commonly used for
GWAS, and the major SNPs that have extraordinarily statistical significance are located
in the TOMM40 gene region and not in APOE. In other words, although findings are
usually referred to in the literature as associated with the AOPE LD region, the
measurements commonly defining this region are rather TOMM40 polymorphisms.
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298 EPMA Journal (2010) 1:293–303Phylogenetic (or genealogical) methods define the rare
and common genetic variants on each strand of DNA in a
region of interest, often selected based on its LD
properties. This strategy significantly decreases the num-
ber of tests for an association study by clustering
haplotypes according to sequence similarity. This similar-
ity is assigned based on inference of the ancestral relation-
ships between the various variants. Once variants are
assigned into initial groups (referred to as clades), an
iterative procedure of inferring subgroupings is employed
until all variants are interconnected into a tree-like spatial
structure. This overall process of tracking back the
sequence of events, from present genetic make-up to
ancestral configuration, and the phasing of polymorphisms
into a branching tree structure is termed “coalescence”.
The assumption is that, due to patterns of inheritance,
haplotypes that contain ‘causal’ variants will be more
related to each other than to haplotypes that do not contain
the causal variant(s) and will therefore cluster into a
distinct clade(s). These risk haplotypes will therefore be
embedded into the tree resultant from the analysis [72]. In
this fashion, it is possible to shrink the overall set of
polymorphisms present in a genomic region (often
amounting to dozens or hundreds) into those that
distinguish between “disease associated” clades and
“control associated” clades. Thus, it is easily possible to
reduce the complexity, multiplicity and computational
burdens typical of conventional association methodology.
The discovery of the LOAD poly-T variant (rs10524523)
was based on a series of experiments conducted sequentially
in Caucasian cohorts, so as to discover genetic variants of
interest in one cohort and confirm the results in independent
datasets. Full details of the discovery and its confirmation,
and the study designs that led to the identification of the
specific genetic variants, were published elsewhere [70].
Overall, these data suggested that a significant genetic
component of AD risk was due to the effect of a co-
dominant variable repeat variant in TOMM40,a c t i n gc i st o
APOE3 and modifying the function of TOMM40 and/or
APOE genes or gene products in some way that impacts
onset of AD. Cis-regulatory elements and structural variants
have previously been implicated in human evolution,
variation, disease susceptibility and complex traits, so this
outcome is not without precedence [73, 74]. In fact, it
has been shown that even few mononucleotide repeat
differences can alter gene expression in yeast [75]a n d
humans [76], as well as modify RNA splicing in mice and
humans [77]. Perhaps the most famous example of a poly-
T tract and its involvement in human disease has been
reported for Cystic Fibrosis. The number of T residues
present in the intron8-exon9 junction in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene
affects splicing efficiency, resulting in reduced amounts
of functional transcripts, which in turn lead to variable
Cystic Fibrosis symptoms [78].
The discovery of the genetic variants responsible for the
majority of variability in age-of-onset of LOAD in itself
does not constitute any benefit to the clinical management
of the disease. In order to prove the clinical validity and
demonstrate clinical utility tailor-designed prospective
clinical trials need to be conducted. To this end, a clinical
trial is being designed, aiming to test the clinical diagnostic
validity of rs10524523 (with or without APOE subtyping)
as a predictor of AD risk and onset in a prospective fashion.
The underlying premise of the study is that the TOMM40
rs10524523 marker, when modeled together with APOE
subtype and age will translate into a more precise prediction
of risk at a particular age than predictions based on APOE
subtype alone. This should be reflected in improved
resolution of the various age-of-onset Kaplan-Meier curves
seen in Fig. 1. In particular, overlapping of the non-E4/E4
carrier curves in Fig. 1, may be due to low sample sizes of
the less common genotype-carrier groups. Alternatively, the
overlap may suggest the existence of additional important
factors, such as other genetic variants or environmental
factors that are involved in the development of the disease
but are unevenly distributed across non-E4/E4 carriers. It is
hypothesized, and remains to be proven in the planned
prospective validation study, that the separation between
Kaplan-Meier curves will improve based on the composite
TOMM40-APOE diagnostic, mainly due to redefinition of
the APOE3-carrier curves according to their haplotypic
relationship to rs10524523 (Fig. 2). The study design
testing this hypothesis presents a pioneering Dx/Rx co-
development approach: the predictive diagnostic validity
study is conducted simultaneously with a prevention (delay
of onset) clinical trial employing a therapeutic agent in
unaffected individuals (http://www.opalstudy.org). Further
details on the possible design of this combination trial as
discussed at the FDA’s Voluntary Exploratory Data
Submission discussions in October 2009 are detailed
elsewhere [79].
Diagnostic utility: genetic and other biomarkers
Plasma, CSF and neuroimaging biomarkers of AD have
been developed to serve as important surrogates of dynamic
changes characteristic of AD progression [59, 80, 81]. They
have been useful in research settings as means to measure
protein-aggregation in plaques, to indicate abnormalities in
metabolism of APP or to pinpoint neuronal degeneration.
Much progress in understanding pathological processes at
early and presymptomatic stages can be gained by
recording changes in hippocampal volume and glucose
metabolism. However, these dynamic biomarkers have
EPMA Journal (2010) 1:293–303 299limited application as stand-alone predictive markers in
healthy individuals prone to develop MCI and later AD,
and their utility in prevention studies is limited to
monitoring changes over time during the course of the
trial. These biomarkers are unlikely to serve as personalized
indicators for early clinical intervention to prevent (or
delay) incipient AD in and of themselves. In addition, the
costs and complexity of these tools prohibit their utility in
population-wide screening programs. By contrast, genetic
tests are suitable for use as high-throughput population-
wide screens, and have already been employed in a
multitude of prevention programs, including those screen-
ing for newborn [82] and prenatal genetic disorders [83],
various cancers [84, 85] and HIV drug-induced adverse-
events [86]. The ease of sample collection (blood, saliva or
buccal swabs), the stable nature of the information
captured, and the low assay costs make genetic tests
uniquely suitable for prediction and prevention applica-
tions. Moreover, genetic tests are widely used in routine
clinical practice, therefore logistics of sample collection and
testing, return of results and reimbursement infrastructure
are in place. In principal, combining various types of
biomarkers together with genetic indicators would likely
yield the optimized positive and negative predictive value
of AD disease onset, MCI conversion and related pheno-
types. However, as outlined above, cost effectiveness and
clinical utility analyses strongly favor diagnostics com-
prised of genetic and demographic data as the core test
components in the vast majority of cases.
In addition to genetic involvement in the susceptibility to
AD and its onset, a significant amount of work has been
devoted to deciphering the genetic makeup associated with
response to AD treatments. The study of genetic determi-
nants associated with drug response phenotypes, including
favorable versus insufficient response, variable pharmaco-
kinetics and drug-induced adverse events, is termed
pharmacogenetics [87, 88]. All currently approved treat-
ments for AD offer temporary relief of some of the
symptoms to merely some of the patients, but they do not
arrest or alter the disease course. These drugs include three
choline esterase inhibitors (ChEIs) for use in mild to
moderate AD management. A fourth medication, an NMDA
(N-methyl-D- aspartate) receptor antagonist, is approved for
moderate to severe AD. Much research has thus been
devoted in recent years to elucidating the role of acetylcho-
linesterase (AChE) and butyrylcholinesterase (BChE) in AD
pathology and ChEI treatment response [89, 90]. Studies in
the last decade, while overall inconclusive, report association
of ChEI efficacy and safety with genetic determinants
located primarily in APOE [91, 92] and the cytochrome
P450 metabolizing enzyme gene CYP2D6 [93, 94]. In
addition, several pharmaceutical development programs of
disease modifying agents have reported response and/or
safety stratification by APOE genotype, although results
await validation. These include Wyeth/Elan’sA β antibody,
bapineuzumab [95, 96]; GlaxoSmithKline’s rosiglitazone
[97]; and Accera’s Ketasyn/Axona [98].
Understanding of the allele frequencies of variants
highly associated with both AD risk/age-of-onset (such as
markers in APOE and TOMM40) and/or pharmacogenetics
(such as markers in APOE or CYP2D6) is especially
important in the context of global clinical trials. Interpre-
tation of the results of the trial without incorporation of
pharmacogenetic data and ethnicity-specific allele frequen-
cy distribution could mask a successful outcome for a
clinical trial, deeming it a failure [99].
Concluding remarks and outlook
The novel approach reviewed above utilizes phylogenetic
methodology to collapse markers into the key polymor-
phisms that associate with complex human diseases. The
key markers are then combined with epidemiological
variables (e.g. age) to predict clinical outcomes. Once the
analytical and clinical validity of the markers are con-
firmed, the diagnostics are tested prospectively for clinical
utility in tandem with a phase-III prevention drug develop-
ment program. In this fashion, trial results are designed to
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Fig. 2 Hypothetical Alzheimer’s disease age of onset curves by
TOMM40-APOE haplotype, based on the information available today
(February 2010). We propose that each of the original AD age of onset
curves is in fact a composite of sub-curves that are defined by
TOMM40 genotype [70, 79]. The APOE4/4 curve would be
unchanged, as the vast majority of APOE4 alleles carry the long (L)
TOMM40 rs10524523 allele. There would be two curves for APOE3/4
individuals due to the presence of either a short (Sh) or a very long
(VL) rs10524523 polymorphism linked to APOE3. There would likely
be three curves for APOE3/3 individuals due to the possible
combination of alleles at rs10524523, i.e. short/short (Sh/Sh), short/
very long (Sh/VL), and very long/very long (VL/VL)
300 EPMA Journal (2010) 1:293–303be directly translatable to healthcare guidance. Overall, this
LOAD example serves as a ground-breaking implementa-
tion of the FDA’s Rx/Dx co-development concept and
paves the way for innovative application in other therapeu-
tic areas, particularly complex disorders and drug response
phenotypes with high estimates of heritability.
In conclusion, AD presents a pioneering example where
research will lead to implementation of every aspect of
predictive, preventive and personalized medicine.T h e
majority of currently available biomarkers serve as tools
during the investigation of disease progression, as well as
during novel drug discovery and development. However,
for the purpose of prediction and prevention the significant
variables are the co-localized genetic markers in TOMM40
and APOE, which account for the vast majority of
variability in both risk and age-of-onset of the disease. In
this fashion, the commonly accepted assumption that
LOAD is underlined by a complex and elaborate set of
genetic markers can potentially be refuted. The complexity
can in fact be disentangled and reduced into a clear and
minimal set of diagnostic markers. Moreover, an expedient
path has been set forth to establish whether or not, and to
what extent, these markers have clinical utility in support-
ing prevention therapy, paving the road for rational health
management and development of insurance reimbursement
programs. It is expected that this and similar approaches
will lead to real personalization of care in AD, as well as
other medical conditions, for the benefit of patients, care
givers and health systems globally.
Acknowledgements Supported by the Deane Drug Discovery
Institute, Cabernet Pharmaceuticals, Inc., Shiraz Pharmaceuticals,
Inc. and Zinfandel Pharmaceuticals, Inc. Additional support came
from NIA grant AG028377. We thank the members of the Institute for
Genomic Sciences and Policy (IGSP) and the Bryan Alzheimer’s
Disease Research Center (ADRC) at Duke University for their
collaborative help.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Matchar DB, ThakurME,GrossmanI,etal.Testingforcytochrome
P450 polymorphisms in adults with non-psychotic depression
treated with selective serotonin reuptake inhibitors (SSRIs). Evid
Rep Technol Assess (Full Rep). 2007;146:1–77. PMID: 17764209.
2. ACCEmodelprocessforevaluatinggenetictests.2009.(Accessedat
http://www.cdc.gov/genomics/gtesting/ACCE/index.htm.)
3. Hughes B. The comparative effectiveness challenge. Nat Rev
Drug Discov. 2009;8(4):261–3. PMID.
4. Ginsburg G, SWillard HF. Genomic and personalized medicine:
foundations and applications. Transl Res. 2009;154(6):277–87.
PMID: 19931193.
5. FDA. Drug-diagnostic co-development concept paper (draft). In;
2005.
6. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the
US population: prevalence estimates using the 2000 census. Arch
Neurol. 2003;60(8):1119–22. PMID: 12925369.
7. National Institute Aging (2005-2006) Progress Report on Alz-
heimers Disease. PMID:
8. Brookmeyer R, Johnson E, Ziegler-Graham K, et al. Forecasting
the global burden of Alzheimer’s disease. Alzheimers Dement.
2007;3(3):186–91. PMID: 19595937.
9. Organization W H. The global burden of disease (2004 update).
In. Geneva, Switzerland: WHO Press; 2004.
10. Blennow K, de Leon M, JZetterberg H. Alzheimer’s disease.
Lancet. 2006;368(9533):387–403. PMID: 16876668.
11. West RL. An application of prefrontal cortex function theory to
cognitive aging. Psychol Bull. 1996;120(2):272–92. PMID:
8831298.
12. Visser PJ, Verhey FR. Mild cognitive impairment as predictor for
Alzheimer’s disease in clinical practice: effect of age and
diagnostic criteria. Psychol Med. 2008;38(1):113–22. PMID:
17451628.
13. Warfarin dosing. 2008. (Accessed at http://www.warfarindosing.
org/Source/Home.aspx.)
14. Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and
environments for explaining Alzheimer disease. Arch Gen
Psychiatry. 2006;63(2):168–74. PMID: 16461860.
15. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a
missense mutation in the amyloid precursor protein gene with
familial Alzheimer’s disease. Nature. 1991;349(6311):704–6.
PMID: 1671712.
16. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene
bearing missense mutations in early-onset familial Alzheimer’s
disease. Nature. 1995;375(6534):754–60. PMID: 7596406.
17. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the
chromosome 1 familial Alzheimer’s disease locus. Science.
1995;269(5226):973–7. PMID: 7638622.
18. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial
Alzheimer’s disease in kindreds with missense mutations in a
gene on chromosome 1 related to the Alzheimer’s disease type 3
gene. Nature. 1995;376(6543):775–8. PMID: 7651536.
19. Campion D, Dumanchin C, Hannequin D, et al. Early-onset
autosomal dominant Alzheimer disease: prevalence, genetic
heterogeneity, and mutation spectrum. Am J Hum Genet.
1999;65(3):664–70. PMID: 10441572.
20. Pericak-Vance MA, Grubber J, Bailey LR, et al. Identification of
novel genes in late-onset Alzheimer’s disease. Exp Gerontol.
2000;35(9–10):1343–52. PMID: 11113612.
21. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of
apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in
late onset families. Science. 1993;261(5123):921–3. PMID: 8346443.
22. Rocchi A, Pellegrini S, Siciliano G, et al. Causative and
susceptibility genes for Alzheimer’s disease: a review. Brain Res
Bull. 2003;61(1):1–24. PMID: 12788204.
23. Bertram LTanzi RE. The genetic epidemiology of neurodegener-
ative disease. J Clin Invest. 2005;115(6):1449–57. PMID:
15931380.
24. Mahley RW. Apolipoprotein E: cholesterol transport protein with
expanding role in cell biology. Science. 1988;240(4852):622–30.
PMID: 3283935.
25. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E:
high-avidity binding to beta-amyloid and increased frequency of type
4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U
S A. 1993;90(5):1977–81. PMID: 8446617.
26. Bertram LTanzi RE. Thirty years of Alzheimer’s disease genetics:
the implications of systematic meta-analyses. Nat Rev Neurosci.
2008;9(10):768–78. PMID: 18802446.
EPMA Journal (2010) 1:293–303 30127. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and
ethnicity on the association between apolipoprotein E genotype
and Alzheimer disease. A meta-analysis. APOE and Alzheimer
Disease Meta Analysis Consortium. JAMA. 1997;278(16):1349–
56. PMID: 9343467.
28. Roses AD. Apolipoprotein E affects the rate of Alzheimer disease
expression: beta-amyloid burden is a secondary consequence
dependent on APOE genotype and duration of disease. J Neuro-
pathol Exp Neurol. 1994;53(5):429–37. PMID: 8083686.
29. Abraham R, Moskvina V, Sims R, et al. A genome-wide
association study for late-onset Alzheimer’s disease using DNA
pooling. BMC Med Genomics. 2008;1:44. PMID: 18823527.
30. Li H, WettenS, Li L, et al. Candidate single-nucleotide polymorphisms
from a genomewide association study of Alzheimer disease. Arch
Neurol. 2008;65(1):45–53. PMID: ISI:000252313000005.
31. Yu C-E, Seltman H, Peskind ER, et al. Comprehensive analysis of
APOE and selected proximate markers for late-onset Alzheimer’s
disease: patterns of linkage disequilibrium and disease/marker
association. Genomics. 2007;89(6):655–65. PMID.
32. Waring SC, Rosenberg RN. Genome-wide association studies in
Alzheimer Disease. Arch Neurol. 2008;65(3):329–34. PMID.
33. Beecham GW, Martin ER, Li YJ, et al. Genome-wide association
study implicates a chromosome 12 risk locus for late-onset
Alzheimer disease. Am J Hum Genet. 2009;84(1):35–43.
34. Waring SC, Rosenberg RN. Genome-wide association studies in
Alzheimer disease. Arch Neurol. 2008;65(3):329–34. PMID:
18332245.
35. Yu CE, Seltman H, Peskind ER, et al. Comprehensive analysis of
APOE and selected proximate markers for late-onset Alzheimer’s
disease: patterns of linkage disequilibrium and disease/marker
association. Genomics. 2007;89(6):655–65. PMID: 17434289.
36. Bu G. Apolipoprotein E and its receptors in Alzheimer’s disease:
pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009;10
(5):333–44. PMID: 19339974.
37. Cedazo-Minguez A. Apolipoprotein E and Alzheimer’s disease:
molecular mechanisms and therapeutic opportunities. J Cell Mol
Med. 2007;11(6):1227–38. PMID: 18205697.
38. Bazrgar M, Karimi M, Fathzadeh M, et al. Apolipoprotein E
polymorphism in Southern Iran: E4 allele in the lowest reported
amounts. Mol Biol Rep. 2008;35(4):495–9. PMID: 17594534.
39. Kok E, Haikonen S, Luoto T, et al. Apolipoprotein E-dependent
accumulation of Alzheimer disease-related lesions begins in
middle age. Ann Neurol. 2009;65(6):650–7. PMID: 19557866.
40. Mayeux R, Saunders AM, Shea S, et al. Utility of the
apolipoprotein E genotype in the diagnosis of Alzheimer’s
disease. Alzheimer’s Disease Centers Consortium on Apolipopro-
tein E and Alzheimer’s Disease. N Engl J Med. 1998;338(8):506–
11. PMID: 9468467.
41. Cichon S, Craddock N, Daly M, et al. Genomewide association
studies: history, rationale, and prospects for psychiatric disorders.
Am J Psychiatry. 2009;166(5):540–56. PMID: 19339359.
42. Bertram L, McQueen MB, Mullin K,et al. Systematicmeta-analyses
of Alzheimer disease genetic association studies: the AlzGene
database. Nat Genet. 2007;39(1):17–23. PMID: 17192785.
43. Lyssenko VGroop L. Genome-wide association study for type 2
diabetes: clinical applications. Curr Opin Lipidol. 2009;20(2):87–
91. PMID: 19276887.
44. McCarthy MI, Zeggini E. Genome-wide association studies in
type 2 diabetes. Curr Diab Rep. 2009;9(2):164–71. PMID:
19323962.
45. Dickson SP, Wang K, Krantz I, et al. Rare variants create synthetic
genome-wide associations. PLoS Biol. 2010;8(1):e1000294.
PMID.
46. Goldstein DB. Common genetic variation and human traits. N
Engl J Med. 2009;360(17):1696–8. PMID: 19369660.
47. Ioannidis JP, Thomas GDaly MJ. Validating, augmenting and
refining genome-wide association signals. Nat Rev Genet.
2009;10(5):318–29. PMID: 19373277.
48. Coon KD, Myers AJ, Craig DW, et al. A high-density whole-
genome association study reveals that APOE is the major
susceptibility gene for sporadic late-onset Alzheimer’s disease. J
Clin Psychiatry. 2007;68(4):613–18. PMID: 17474819.
49. Potkin SG, Guffanti G, Lakatos A, et al. Hippocampal atrophy as
a quantitative trait in a genome-wide association study identifying
novel susceptibility genes for Alzheimer’s disease. PLoS One.
2009;4(8):e6501. PMID: 19668339.
50. Harold D, Abraham R, Hollingworth P, et al. Genome-wide
association study identifies variants at CLU and PICALM
associated with Alzheimer’s disease. Nat Genet. 2009;41
(10):1088–93. PMID: 19734902.
51. Lambert JC, Heath S, Even G, et al. Genome-wide association study
identifies variants at CLU and CR1 associated with Alzheimer’s
disease. Nat Genet. 2009;41(10):1094–9. PMID: 19734903.
52. Heinzen EL, Need AC, Hayden KM et al. Genome-wide scan of
copy number variation in late-onset Alzheimer's disease. J
Alzheimers Dis. 2009. PMID: 19749422
53. Carrasquillo MM, Zou F, Pankratz VS, et al. Genetic variation in
PCDH11Xis associated with susceptibility to late-onset Alzheimer’s
disease. Nat Genet. 2009;41(2):192–8. PMID: 19136949.
54. Grupe A, Abraham R, Li Y, et al. Evidence for novel
susceptibility genes for late-onset Alzheimer’s disease from a
genome-wide association study of putative functional variants.
Hum Mol Genet. 2007;16(8):865–73. PMID: 17317784.
55. Reiman EM, Webster JA, Myers AJ, et al. GAB2 alleles modify
Alzheimer’s risk in APOE epsilon4 carriers. Neuron. 2007;54
(5):713–20. PMID: 17553421.
56. Bertram L, Lange C, Mullin K, et al. Genome-wide association
analysis reveals putative Alzheimer’s disease susceptibility loci in
addition to APOE. Am J Hum Genet. 2008;83(5):623–32. PMID:
18976728.
57. Blass JP, Gibson GE. Cerebrometabolic aspects of delirium in
relationship to dementia. Dement Geriatr Cogn Disord. 1999;10
(5):335–8. PMID: 10473934.
58. Davis JN, Hunnicutt EJ, Jr CJC. A mitochondrial bottleneck
hypothesis of Alzheimer’s disease. Mol Med Today. 1995;1
(5):240–7. PMID: 17607886.
59. Kessler J, Herholz K, Grond M, et al. Impaired metabolic
activation in Alzheimer’s disease: a PET study during continuous
visual recognition. Neuropsychologia. 1991;29(3):229–43. PMID:
2057055.
60. Blass JP. The mitochondrial spiral. An adequate cause of dementia
in the Alzheimer’s syndrome. Ann N Y Acad Sci. 2000;924:170–
83. PMID: 11193795.
61. Castellani R, Hirai K, Aliev G, et al. Role of mitochondrial
dysfunction in Alzheimer’s disease. J Neurosci Res. 2002;70
(3):357–60. PMID: 12391597.
62. Manczak M, Anekonda TS, Henson E, et al. Mitochondria are a
direct site of A beta accumulation in Alzheimer’s disease neurons:
implications for free radical generation and oxidative damage in
disease progression. Hum Mol Genet. 2006;15(9):1437–49.
PMID: 16551656.
63. Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction
and synaptic damage: implications for cognitive decline in aging
and Alzheimer’s disease. Trends Mol Med. 2008;14(2):45–53.
PMID: 18218341.
64. Rui Y, Tiwari P, Xie Z, et al. Acute impairment of mitochondrial
trafficking by beta-amyloid peptides in hippocampal neurons. J
Neurosci. 2006;26(41):10480–7. PMID: 17035532.
65. Devi L, Prabhu BM, Galati DF, et al. Accumulation of amyloid
precursor protein in the mitochondrial import channels of human
302 EPMA Journal (2010) 1:293–303Alzheimer’s disease brain is associated with mitochondrial
dysfunction. J Neurosci. 2006;26(35):9057–68. PMID: 16943564.
66. Brodbeck J, Balestra ME, Saunders AM, et al. Rosiglitazone
increases dendritic spine density and rescues spine loss caused by
apolipoprotein E4 in primary cortical neurons. Proc Natl Acad Sci
U S A. 2008;105(4):1343–6. PMID: 18212130.
67. Chang S, Ran Ma T, Miranda RD, et al. Lipid- and receptor-
binding regions of apolipoprotein E4 fragments act in concert to
cause mitochondrial dysfunction and neurotoxicity. Proc Natl
Acad Sci U S A. 2005;102(51):18694–9. PMID: 16344479.
68. Anandatheerthavarada HK, Biswas G, Robin MA, et al. Mito-
chondrial targeting and a novel transmembrane arrest of Alzheimer’s
amyloid precursor protein impairs mitochondrial function in neuro-
nal cells. J Cell Biol. 2003;161(1):41–54. PMID: 12695498.
69. Hansson Petersen CA, Alikhani N, Behbahani H, et al. The
amyloid beta-peptide is imported into mitochondria via the TOM
import machinery and localized to mitochondrial cristae. Proc Natl
Acad Sci U S A. 2008;105(35):13145–50. PMID: 18757748.
70. Roses AD, Lutz MW, Amrine-Madsen H et al. A TOMM40
variable-length polymorphism predicts the age of late-onset
Alzheimer’s disease. Pharmacogenom J. 2009. PMID: 20029386.
71. Bekris LM, Millard SP, Galloway NM, et al. Multiple SNPs
within and surrounding the apolipoprotein E gene influence
cerebrospinal fluid apolipoprotein E protein levels. J Alzheimers
Dis. 2008;13(3):255–66. PMID: 18430993.
72. Tachmazidou I, JDe VC, Iorio M. Genetic association mapping
via evolution-based clustering of haplotypes. PLoS Genet. 2007;3
(7):e111. PMID: 17616979.
73. Frazer KA, Murray SS, Schork NJ, et al. Human genetic variation
and its contribution to complex traits. Nat Rev Genet. 2009;10
(4):241–51. PMID: 19293820.
74. Wray GA. The evolutionary significance of cis-regulatory
mutations. Nat Rev Genet. 2007;8(3):206–16. PMID: 17304246.
75. Biswas TK, Getz GS. Position-specific inhibition of yeast
mitochondrial transcription by a poly(T) sequence. J Mol Biol.
1998;275(4):547–60. PMID: 9466930.
76. Beyer K, Humbert J, Ferrer A, et al. A variable poly-T sequence
modulatesalpha-synuclein isoform expressionand isassociated with
aging. J Neurosci Res. 2007;85(7):1538–46. PMID: 17387688.
77. Hegde S, Lenox LE, Lariviere A, et al. An intronic sequence
mutated in flexed-tail mice regulates splicing of Smad5. Mamm
Genome. 2007;18(12):852–60. PMID: 18060457.
78. Chu CS, Trapnell BC, Curristin S, et al. Genetic basis of
variable exon 9 skipping in cystic fibrosis transmembrane
conductance regulator mRNA. Nat Genet. 1993;3(2):151–6.
PMID: 7684646.
79. Lutz MW, Crenshaw DG, Saunders AM et al. Perspectives:
genetic variation at a single locus and age of onset for Alzheimer’s
disease. Alzheimer’s and Dementia. 2010. PMID:
80. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-
amyloid peptide42 in the cerebrospinal fluid of patients with
Alzheimer’s disease. AnnNeurol. 1995;38(4):643–8. PMID: 7574461.
81. Jagust WJ, Landau SM, Shaw LM, et al. Relationships between
biomarkers in aging and dementia. Neurology. 2009;73(15):1193–
9. PMID: 19822868.
82. Fernhoff PM. Newborn screening for genetic disorders. Pediatr
Clin North Am. 2009;56(3):505–13. Table of Contents. PMID:
19501689.
83. Rosner G, Rosner SOrr-Urtreger A. Genetic testing in Israel: an
overview. Annu Rev Genomics Hum Genet. 2009;10:175–92.
PMID: 19453249.
84. Hahn NM, Kelley MR, Klaunig JE, et al. Constitutional poly-
morphisms of prostate cancer: prognostic and diagnostic implica-
tions. Future Oncol. 2007;3(6):665–82. PMID: 18041919.
85. Palomaki GE, Steinort K, Knight GJ, et al. Comparing three
screening strategies for combining first- and second-trimester
Down syndrome markers. Obstet Gynecol. 2006;107(2 Pt 1):367–
75. PMID: 16449126.
86. Lalonde RG, Thomas R, Rachlis A et al. Successful implemen-
tation of a national HLA-B*5701 genetic testing service in
Canada. Tissue Antigens. 2009. PMID: 19843279.
87. Grossman I. Routine pharmacogenetic testing in clinical practice:
dream or reality? Pharmacogenomics. 2007;8(10):1449–59.
PMID: 17979518.
88. Roses AD. The medical and economic roles of pipeline
pharmacogenetics: Alzheimer’s disease as a model of efficacy
and HLA-B(*)5701 as a model of safety. Neuropsychopharma-
cology. 2009;34(1):6–17. PMID: 18923406.
89. Berson A, Knobloch M, Hanan M, et al. Changes in readthrough
acetylcholinesterase expression modulate amyloid-beta pathology.
Brain. 2008;131(Pt 1):109–19. PMID: 18056160.
90. Podoly E, Shalev DE, Shenhar-Tsarfaty S, et al. The butyrylcholi-
nesterase K variant confers structurally derived risks for Alzheimer
pathology. J Biol Chem. 2009;284(25):17170–9. PMID: 19383604.
91. Sjogren M, Hesse C, Basun H, et al. Tacrine and rate of progression
in Alzheimer’s disease–relation to ApoE allele genotype. J Neural
Transm. 2001;108(4):451–8. PMID: 11475012.
92. Choi SH, Kim SY, Na HR, et al. Effect of ApoE genotype on
response to donepezil in patients with Alzheimer’s disease.
Dement Geriatr Cogn Disord. 2008;25(5):445–50. PMID:
18401173.
93. Cacabelos R, Llovo R, Fraile C, et al. Pharmacogenetic aspects of
therapy with cholinesterase inhibitors: the role of CYP2D6 in
Alzheimer’s disease pharmacogenetics. Curr Alzheimer Res.
2007;4(4):479–500. PMID: 17908053.
94. Varsaldi F, Miglio G, Scordo MG, et al. Impact of the CYP2D6
polymorphism on steady-state plasma concentrations and clinical
outcome of donepezil in Alzheimer’s disease patients. Eur J Clin
Pharmacol. 2006;62(9):721–6. PMID: 16845507.
95. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple
ascendingdosetrialofbapineuzumabinmildtomoderateAlzheimer
disease. Neurology. 2009;73(24):2061–70. PMID: 19923550.
96. Kaufer D, Gandy S. APOE {epsilon}4 and bapineuzumab:
Infusing pharmacogenomics into Alzheimer disease therapeutics.
Neurology. 2009;73(24):2052–3. PMID: 19923549.
97. Risner ME, Saunders AM, Altman JF, et al. Efficacy of
rosiglitazone in a genetically defined population with mild-to-
moderate Alzheimer’s disease. Pharmacogenomics J. 2006;6
(4):246–54. PMID: 16446752.
98. Costantini LC, Barr LJ, Vogel JL, et al. Hypometabolism as a
therapeutic target in Alzheimer’s disease. BMC Neurosci. 2008;9
Suppl 2:S16. PMID: 19090989.
99. Akkari PA, Swanson TW, Crenshaw DG, et al. Pipeline
pharmacogenetics: a novel approach to integrating pharmaco-
genetics into drug development. Curr Pharm Des. 2009;15
(32):3754–63. PMID: 19925426.
EPMA Journal (2010) 1:293–303 303